Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

Infection Control and Hospital Epidemiology

Volumn 36, Issue 4, 2015, Pages 438-444

  Varier, Raghu U ^a,e   Biltaji, Eman ^b   Smith, Kenneth J ^c   Roberts, Mark S ^d   Jensen, M Kyle ^a   LaFleur, Joanne ^b   Nelson, Richard E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; FECAL MICROBIOTA TRANSPLANTATION; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; MONTE CARLO METHOD; PRACTICE GUIDELINE; QUALITY OF LIFE; RECURRENT CLOSTRIDIUM DIFFICILE INFECTION; RECURRENT INFECTION; SENSITIVITY ANALYSIS; ADULT; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMICS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; PEPTOCLOSTRIDIUM DIFFICILE; QUALITY ADJUSTED LIFE YEAR;

ADULT; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; HEALTH CARE COSTS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; VANCOMYCIN;

EID: 84955065979     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2014.80     Document Type: Article

References (43)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-415.
2. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007;13:1417-1419.
3. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009;48:568-576.
4. Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 2008;14:691-692.
5. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-498-quiz 499.
6. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014; 42:43-59.
7. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97:1769-1775.
8. Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm 2013;66: 361-368.
9. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403-410.
10. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044-1049.
11. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500-508.
12. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-415.
13. Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013;108:177-185.
14. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107: 1079-1087.
15. Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C. difficile infection: ready for prime time? Cleveland Clin J Med 2013;80:101-108.
16. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointestinal Endoscopy 2013;78:240-249.
17. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 2012;5:403-420.
18. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012;35:865-875.
19. Borody TJ, Campbell J. Fecal microbiota transplantation. Gastroenterol Clin NA 2012;41:781-803.
20. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507-1514.
21. Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis 2012;31:3163-3171.
22. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
23. Figueroa I, Johnson S, Sambol SP, Goldstein EJC, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012;55:S104-S109.
24. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638-658.
25. Ko CW, Dominitz JA. Complications of colonoscopy: magnitude and management. Gastrointestinal Endosc Clin NA 2010;20: 659-671.
26. Consumer Price Index. ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt. Published 2014. Accessed January 14, 2014.
27. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104.
28. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013;57:555-561.
29. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297-304.
30. Constantinides VA, Heriot A, Remzi F, et al. Operative strategies for diverticular peritonitis: a decision analysis between primary resection and anastomosis versus Hartmann's procedures. Ann Surg 2007;245:94-103.
31. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ 2011;20:2-15.
32. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010;96:5-21.
33. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009;12:S5-S9.
34. Physician Fee Schedule Search Results. Centers for Medicare and Medicaid Services website. http://www.cms.gov/apps/physicianfee-schedule/search/search-results.aspx?Y=3&T=0&HT=0&CT=3 &H1=45378&M=5. Published 2010. Accessed January 14, 2014.
35. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109:1065-1071.
36. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-455.
37. Kunimoto D, Thomson AB. Recurrent Clostridium difficile-associated colitis responding to cholestyramine. Digestion 1986; 33:225-228.
38. Yamazaki S, Nakamura H, Yamagata S, et al. Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency. Int J Clin Pharmacol Ther 2009;47:701-706.
39. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014;8:252-253.
40. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013;11:1036-1038.
41. Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal transplant. Clin Infect Dis 2014;59:319-319.
42. Infectious Diseases Society of America. Fecal transplant pill knocks out recurrent C. diff infection. ScienceDaily, 4 October 2013. www.sciencedaily.com/releases/2013/10/131004105253. htm. Published 2014. Accessed January 27, 2014.
43. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-431.